Denileukin diftitox + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell, Peripheral
Conditions
Lymphoma, T-Cell, Peripheral
Trial Timeline
Mar 14, 2004 → Dec 23, 2009
NCT ID
NCT00211185About Denileukin diftitox + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone
Denileukin diftitox + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone is a phase 2 stage product being developed by Eisai for Lymphoma, T-Cell, Peripheral. The current trial status is completed. This product is registered under clinical trial identifier NCT00211185. Target conditions include Lymphoma, T-Cell, Peripheral.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00211185 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell, Peripheral